Total Funding
70
68
Total FundingPost-IPO Equity raised
Growth Score
-8 pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
39821
InnoCare is a Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases.
- Jasmine Cui: President & CEOPast Role: Merck, Director,
- Xiangyang Chen: VP of ChemistryPast Role: BioDuro, ED of Medicinal Chemistry
About the Company
InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. InnoCare' s core scientific team members have strong educational backgrounds and rich drug innovation experiences in the U.S. and China. InnoCare also has an elite Scientific Advisory Board
(SAB) comprising of professionals from leading universities, hospitals, academic institutions and pharmaceutical industry. InnoCare is forging forward on the critical path of defeating diseases and pushing the boundaries of innovation into unchartered territories.
